Figure 1: Reduction in the amount of F. prausnitzii in Inflammatory Bowel Diseases (IBD) patients. Sokol et al. IBD 2009
Figure 2: F. prausnitzii proportions at time of surgery according to the endoscopic recurrence status at 6 months (Sokol & al. 2008)
Figure 3: F. prausnitzii level at Infliximab discontinuation in CD patients Vs Relapse free survival rate (Rajca et al. IBD 2014)
Figure 4: Correlation F. prausnitzii and number of years to intestinal resection or colectomy (Shapiro et al. Cell Host & Microbe 2020)


Faecalibacterium Prausnitzii IN INFLAMMATORY BOWEL DISEASES

Faecalibacterium prausnitzii (F. prau) to Fight Crohn’s Disease
A key intestinal bacterium associated with targeted modulating effects on the host’s immune system.

In 2008, Exeliom Bioscience co-founders were the first to demonstrate and publish the anti-inflammatory properties of F. prausnitzii (Sokol H, et al.). Since this discovery, the therapeutic potential of F. prau has been widely confirmed by both researchers and their peers globally. Here are the conclusions we can draw:

  • Low levels of F. prausnitzii are a sign of illness: (1) The F. prausnitzii  concentration level is decreased in patients suffering from inflammatory bowel diseases (Figure 1). (2) A reduction in the intestinal concentration of F. prausnitzii is associated with a higher risk of the postoperative recurrence of Crohn’s disease. (3) Low F. prausnitzii  levels have also been associated with higher relapse risks.
  • Good levels of F. prausnitzii are a sign of wellness. (1) For Crohn’s disease patients in remission, a high level of F. prausnitzii  is associated with remission maintenance, while a low level is associated with a higher risk of clinical flare-ups (Figure 2). (2) A high level of F. prausnitzii  is associated with a better response to current treatments (Figure 3). (3) A high level of F. prausnitzii  is associated with a lower need for surgery (Figure 4). (4) A high abundance of F. prausnitzii  has never been associated with any infections or any other disease in humans.
F. prausnitzii is therefore a unique bacterial species that plays a critical role in inflammatory bowel diseases.
As they are lacking this bacterium, Crohn’s disease patients do not have a fair chance to improve their condition. Increasing the level of F. prausnitzii  in patients, by administering EXL01 for instance, could possibly lead to longer remission periods, a lower need for surgery, and an overall improved quality of life.
In other words, our lead candidate EXL01, a single F. prausnitzii  strain drug-product, aims at giving patients a fair chance to fight.
Learn more about how EXL01 is being used in Crohn’s disease
Learn more about F. prau


F. prau in cancer immunotherapy



Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.